There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of the patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characterisitic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.

The present invention describes a method for detecting NEPC in a patient afflicted with prostate cancer comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to detect circulating tumor cells (CTC), and (b) determining presence or absence of a CTC subpopulation associated with NEPC comprising detecting a measurable feature of each biomarker in a panel of morphological and protein biomarkers, wherein the presence of the CTC subpopulation associated with NEPC is indicative of NEPC. In other embodiments, the biomarkers for the CTC subpopulation associated with NEPC comprise small size, absence of Androgen Receptor (AR.sup.−), and presence of nucleoli (nucleoli.sup.+). In additional embodiments, the methods of the invention further comprise molecular analysis of the CTCs.

Disclosed herein are methods of diagnosing and treating a subject with prostate cancer, as well as methods of monitoring the responsiveness of a subject having prostate cancer to a therapeutic agent.

The present invention relates to compositions and methods for the in vitro diagnosis of prostate cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.

The present invention generally relates to a method of diagnosing, prognosing and treating prostate cancer patients. Particularly, the present invention relates to a method of selecting patients with castration resistant prostate cancer (CrPC) for combination therapy comprising a selective dipeptidyl peptidase inhibitor and a PD-1 axis antagonist. The present invention provides a computational approach to identifying potential patients for CrPC. The present invention also relates to a method of treating castration resistant prostate cancer (CrPC) patients with said combination therapy.

An antibody or antigen-binding portion thereof which binds to PSMA and comprises a heavy chain variable domain comprising the sequence given in SEQ ID NO:33, wherein SEQ ID NO:33 is: EVQLVQSGX.sup.9E X.sup.11KKPGASVKV SCKX.sup.24SGYTFT EYTIHWVX.sup.38QA X.sup.41 GKGLEWIGN INPNX.sup.55GGTTY NOKFEDRX.sup.68TX.sup.70 TVDKSTSTAY MELSSLRSED TAVYYCAAGW NFDYWGOGTT VTVSS wherein: X.sup.9 is A or P X.sup.11 is V or L X.sup.24 is A or T X.sup.38 is R or K X.sup.41 is P or H X.sup.55 is N or Q X.sup.68 is V or A; and X.sup.70 is I or L whereby the heavy chain variable domain comprises up to 3 amino acid sequence modification(s) between positions 1-30, 36-49, 67-98 and 105-115 of SEQ ID NO: 33. The invention also provides compounds that include the antibody or antigen-binding portion thereof, such as conjugates, and their use in the treatment or diagnosis of diseases, in particular cancers, particularly prostate cancer.

The method of the present invention classifies the nuclei in prostate tissue images with a trained deep learning network and uses said nuclear classification to classify regions, such as glandular regions, according to their malignancy grade. The method according to the present disclosure also trains a deep learning network to identify the category of each nucleus in prostate tissue image data, said category representing the malignancy grade of the tissue surrounding the nuclei. The method of the present disclosure automatically segments the glands and identifies the nuclei in a prostate tissue data set. Said segmented glands are assigned a category by at least one domain expert, and said category is then used to automatically assign a category to each nucleus corresponding to the category of said nucleus' surrounding tissue. A multitude of windows, each said window surrounding a nucleus, comprises the training data for the deep learning network.

The present disclosure relates human antibodies, or antigen binding fragments thereof, able to bind prostasomes, and to prostate cancer diagnosis and prognosis. More specifically, the proposed technique relates to methods for diagnosing prostate cancer using human antibodies, or antigen binding fragments thereof, for detecting prostasomes in body fluids. The disclosure comprises human antibodies able to specifically and selectively detect prostasomes in body fluids, and methods for diagnosing prostate cancer using the human antibodies. The disclosure further comprises providing prognosis, evaluating the severity of the prostate cancer and determining the efficacy of a medical treatment of the prostate cancer.

The present application is directed to a theranostic probe and its use for targeting and/or labeling the EGFR kinase and/or the cells expressing EGFR or its family members.